Trial Profile
Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GMMG-CONCEPT
- 27 Sep 2023 prespecified interim results published in the Journal of Clinical Oncology
- 22 Jan 2023 Planned End Date changed from 1 Jul 2024 to 1 Sep 2026.
- 22 Jan 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Feb 2025.